Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 80INDUSTRY 25NIH 5OTHER_GOV 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 3Leukemia 3Burkitt Lymphoma 3Solid Tumors 1Solid Tumor 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lymphoma 1Hematologic Neoplasms 1Hematologic Diseases 1Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited 1

Interventions

Vinorelbine 3Gemcitabine 3Ifosfamide 2Cyclophosphamide 2zanubrutinib 1treosulfan 1plerixafor 1pegylated granulocyte colony-stimulating factor 1obinutuzumab 1ibritumomab tiuxetan 1fludarabine 1entecavir 1Thiotepa 1Rituximab 1Ice 1Guanosine Diphosphate 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Etoposide 1EPOCH protocol 1Drug Therapy 1Cytarabine 1CVAD protocol 11-(1-glycero)dodeca-1,3,5,7,9-pentaene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Lymphoma, Non-Hodgkin × fludarabine × Clear all
NCT06160362 2023-12-07

The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)

Henan Cancer Hospital

Phase NA Unknown
20 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡